Willem J.S. de Villiers

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Paul Rutgeerts, William J. Sandborn, Brian G. Feagan et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

William J. Sandborn, Christopher Gasink, Long-Long Gao et al. · New England Journal of Medicine · 2012 · 1.1K citations

Life Sciences, Immunology, Pharmacotherapy +17

Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab

William J. Sandborn, Paul Rutgeerts, Brian G. Feagan et al. · Gastroenterology · 2009 · 472 citations · Full text

Medicine, Surgery, Gastroenterology +10

Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial

William J. Sandborn, Rory Rebuck, Yuhua Wang et al. · Clinical Gastroenterology and Hepatology · 2021 · 240 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

SR-BII, an Isoform of the Scavenger Receptor BI Containing an Alternate Cytoplasmic Tail, Mediates Lipid Transfer between High Density Lipoprotein and Cells

Nancy R. Webb, Patrice M. Connell, Gregory A. Graf et al. · Journal of Biological Chemistry · 1998 · 221 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15